4-氨基苯基吗啉-4-基甲酮 | 51207-86-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氨基苯基吗啉-4-基甲酮
• 中文别名: N-(4-胺基苯酰基)吗啡啉；(4-氨基苯基)(4-吗啉基)甲酮；(4-氨基苯基)-吗啉-4-甲酮
• 英文名称: (4-amino-phenyl)-morpholin-4-yl-methanone
• 英文别名: (4-aminophenyl)(morpholino)methanone；4-(morpholinocarbonyl)aniline；4-(4-aminobenzoyl)morpholine；(4-aminophenyl)(4-morpholinyl)methanone；1-(4-amino-phenyl)-1-morpholin-4-yl-methanone；(4-aminophenyl)-morpholin-4-ylmethanone
• CAS: 51207-86-4
• 化学式: C₁₁H₁₄N₂O₂
• mdl: MFCD00158788
• 分子量: 206.244
• InChiKey: WEHVQIQNGXWTME-UHFFFAOYSA-N

物化性质

• 熔点：
  132-135°C
• 沸点：
  426.9±40.0 °C(Predicted)
• 密度：
  1.228±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: (4-Aminophenyl)(morpholino)methanone
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: (4-Aminophenyl)(morpholino)methanone
CAS number: 51207-86-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H14N2O2
Molecular weight: 206.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氨基苯基吗啉-4-基甲酮 在 盐酸 、 亚硝酸特丁酯 、 二碘甲烷 、 四丁基高氯酸铵 作用下， 以 甲醇 、 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.5h， 以53%的产率得到4-(4-碘苯甲酰基)吗啉
  参考文献：
  名称：

  Sandmeyer反应的一般电化学策略†

  摘要：

  本文中，我们报告了桑德迈尔反应的一般电化学策略。使用电作为驱动力，该协议采用一种简单且廉价的卤素源，例如NBS，CBrCl 3，CH 2 I 2，CCl 4，LiCl和NaBr进行芳基重氮盐的卤化。另外，我们发现这些电化学反应可以以一锅的方式使用苯胺作为起始原料来进行。此外，该方法的实用性在使用非常便宜的石墨作为电极的多克规模的芳基卤化物的合成中得到了证明。已经进行了一系列详细的机理研究，包括自由基时钟和自由基清除剂研究，循环伏安分析和原位电子顺磁共振（EPR）分析。

  DOI：

  10.1039/c8sc03346c
• 作为产物：
  描述：

  对碘苯胺 在 copper(l) iodide 、 lithium chloride 、 锌 作用下， 以 四氢呋喃 为溶剂， 反应 25.0h， 生成 4-氨基苯基吗啉-4-基甲酮
  参考文献：
  名称：

  直接制备新型有机锌试剂，氨基苯基碘化锌及其应用

  摘要：

  通过将活性锌直接插入具有酸性质子的碘代苯胺中，可以轻松而有效地产生新的有机锌试剂，即4-氨基苯基碘化锌（A）和3-氨基苯基碘化锌（B）。后来有机锌与各种酰氯的偶合反应被证明是制备氨基苯基酮的有效工具。

  DOI：

  10.1016/j.tetlet.2015.01.053
• 作为试剂：
  描述：

  4-氨基苯基吗啉-4-基甲酮 、 lithium hexamethyldisilazane 、 2,6-二氯烟酸 在 氮气 、 二氧化碳 、 四氢呋喃 、 4-氨基苯基吗啉-4-基甲酮 、 水 、 盐酸 、 甲醇 、 二氯甲烷 作用下， 以 四氢呋喃 为溶剂， 反应 17.25h， 以to give 6.60 g of 6-chloro-2-(4-(morpholine-4-carbonyl)phenylamino)nicotinic acid as a white solid的产率得到6-chloro-2-(4-(morpholine-4-carbonyl)phenylamino)nicotinic acid
  参考文献：
  名称：

  NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS

  摘要：

  本发明涉及一种公式（I）的烟酰胺化合物，或其立体异构体或其药学上可接受的盐。还公开了使用这种化合物治疗至少一种Btk相关疾病的方法，例如炎症性疾病，并且还公开了包含这种化合物的药物组合物。

  公开号：

  US20120082702A1

文献信息

• [EN] PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS<br/>[FR] PYRROLOTRIAZINES EN TANT QU'INHIBITEURS D'ALK ET DE JAK2
  申请人：CEPHALON INC

  公开号：WO2010071885A1

  公开（公告）日：2010-06-24

  The present invention provides a compound of formula (I) or a salt form thereof, wherein Q1, Q2, Q3, and Q4 are as defined herein. The compound of formula (I) has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供了一种式（I）的化合物或其盐形式，其中Q1、Q2、Q3和Q4如本文所定义。式（I）的化合物具有ALK和/或JAK2抑制活性，并可用于治疗增殖性疾病。
• [EN] CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES<br/>[FR] LIBÉRATION CONTRÔLÉE À PARTIR DE CONJUGUÉS MACROMOLÉCULAIRES
  申请人：PROLYNX LLC

  公开号：WO2011140393A1

  公开（公告）日：2011-11-10

  The invention relates to conjugates of macromolecular carriers and drugs comprising linkers that release the drug or a prodrug through rate-controlled beta-elimination, and methods of making and using the conjugates.

  这项发明涉及大分子载体和药物的共轭物，包括释放药物或前药的连接剂，通过速率控制的β-消除释放药物，以及制备和使用这些共轭物的方法。
• [EN] 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES<br/>[FR] 2 -ARYLAMINOQUINAZOLINES DESTINÉES AU TRAITEMENT DES MALADIES PROLIFÉRATIVES
  申请人：NOVARTIS AG

  公开号：WO2009153313A1

  公开（公告）日：2009-12-23

  The invention provides novel compounds that are inhibitors of PDKI. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or composition.

  这项发明提供了一种抑制PDKI的新型化合物。还提供了包括这些化合物的药物组合物，以及使用这些化合物或组合物治疗增殖性疾病，如癌症的方法。
• Therapeutic heterocyclic compounds
  申请人：——

  公开号：US20030013708A1

  公开（公告）日：2003-01-16

  Provided herein is a compound having the formula (I): 1 Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT 1B and 5HT 1D antagonists.

  本文提供的化合物具有以下式（I）： 其中所述化合物可用于治疗精神障碍，包括但不限于抑郁症、广泛性焦虑、进食障碍、痴呆症、恐慌障碍和睡眠障碍。这些化合物还可能用于治疗胃肠道障碍、心血管调节、运动障碍、内分泌障碍、血管痉挛和性功能障碍。这些化合物是5HT 1B和5HT 1D拮抗剂。
• Therapeutic chromone compounds
  申请人：——

  公开号：US20040087575A1

  公开（公告）日：2004-05-06

  Provided herein is a compound of the formula (I) wherein said compound is useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating, disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT 1B antagonists. Also provided herein are processes for making compounds of Formula (I) and intermediate compounds.

  本文提供的是一种化合物，其化学式为（I），其中该化合物可用于治疗包括但不限于抑郁症、广泛性焦虑、进食障碍、痴呆症、恐慌障碍和睡眠障碍在内的精神疾病。这些化合物也可能对治疗胃肠道疾病、心血管调节、运动障碍、内分泌失调、血管痉挛和性功能障碍有用。这些化合物是5HT 1B 拮抗剂。本文还提供了制备化合物（I）和中间体化合物的方法。